MO HealthNet (Medicaid) is conducting a survey regarding the implementation of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act’s prescription drug monitoring program mandate. The SUPPORT Act required that states mandate that covered providers consult a qualified prescription drug monitoring program (PDMP) before prescribing controlled substances to covered individuals. States must report annual data about the use of PDMPs by covered providers before prescribing controlled substances to the Department of Health and Human Services (HHS).
Also in Missouri, effective January 9, 2025, the MO HealthNet Division (MHD) carved-out certain drugs from the 340B Drug Pricing Program reimbursement. It was necessary to allow the state to collect supplemental and value-based agreement rebates on certain therapies. The state cannot collect federal, supplemental, or value-based agreement rebates when a covered entity utilizes 340B stock.
For more information, contact NACDS’ Mary Staples at 817-442-1155.